Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease,Hepatology

当前位置： X-MOL 学术 › Hepatology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease
Hepatology ( IF 12.9 ) Pub Date : 2021-12-22 , DOI: 10.1002/hep.32294
Xinrong Zhang _{1,

2,

3} , Grace Lai‐Hung Wong _{1,

2,

3} , Terry Cheuk‐Fung Yip _{1,

2,

3} , Yee‐Kit Tse _{1,

2,

3} , Lilian Yan Liang _{1,

2,

3} , Vicki Wing‐Ki Hui _{1,

2,

3} , Huapeng Lin _{1,

2,

3} , Guan‐Lin Li _{1,

2,

3} , Jimmy Che‐To Lai _{1,

2,

3} , Henry Lik‐Yuen Chan _{2,

4} , Vincent Wai‐Sun Wong _{1,

2,

3}

Affiliation

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can inhibit liver fibrogenesis in animal models. We aimed to evaluate the impact of ACEI/ARB use on the risk of liver cancer and cirrhosis complications in patients with NAFLD.

中文翻译：